CD24Fc

Unassigned

New Medicines

Graft versus host disease (GvHD) - prevention

Information

New molecular entity
OncoImmune
OncoImmune

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Biologic that fortifies an innate immune checkpoint against excessive inflammation caused by tissue injury
GvHD is related to the degree of HLA mismatch, typical signs include skin gastrointestinal or liver symptoms. It is graded from Stage I (milder symptoms) to Stage IV (severe). Around 40% of patients who receive an HLA-matched transplant will still develop acute GvHD, probably resulting from other genetic differences [2].
Graft versus host disease (GvHD) - prevention
Intravenous infusion